- In May 2024, Elekta AB, a leading innovator in precision radiation medicine, announced the launch of Elekta Harmony Pro, an advanced linear accelerator designed to streamline IMRT treatment workflows. This next-generation platform integrates AI-assisted planning and real-time imaging to deliver faster, more accurate treatments while reducing patient setup time. The launch reflects Elekta’s commitment to improving patient outcomes and operational efficiency in oncology departments worldwide
- In April 2024, Varian, a Siemens Healthineers company, expanded its Adaptive Intelligence technology suite across multiple IMRT platforms. This enhancement enables real-time treatment adaptation based on tumor motion and anatomical changes, improving precision in complex cancer cases. The development underscores Varian’s leadership in AI-driven radiotherapy and its focus on personalized, high-accuracy cancer care
- In March 2024, Accuray Incorporated unveiled the Radixact 2.0 System with Synchrony for adaptive IMRT, offering clinicians continuous target tracking during treatment. The system enables automated dose modulation to account for patient movement, particularly in thoracic and abdominal cancers. This innovation aims to boost clinical confidence and treatment accuracy, especially for tumors located near vital organs
- In February 2024, ViewRay Inc. completed the installation of its MRIdian Linac system in a major cancer center in South Korea, bringing real-time MRI-guided IMRT capabilities to the region. This milestone represents a growing global demand for image-guided and adaptive radiotherapy technologies, especially in Asia-Pacific markets where cancer incidence is rapidly increasing
- In January 2024, RaySearch Laboratories partnered with Brainlab AG to integrate their RayStation® treatment planning system with Brainlab’s ExacTrac Dynamic platform. This collaboration enhances IMRT delivery through high-precision patient positioning and motion monitoring, optimizing treatment accuracy and safety. The partnership reflects an industry-wide shift toward interoperability and end-to-end oncology solutions tailored for complex cancer cases
